BiotechTube

UB-313 + Placebo

Phase 1Completed
0 watching 0 views this week💤 Quiet
25
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Migraine

Conditions

Migraine

Trial Timeline

Jul 6, 2022 → Oct 6, 2023

NCT ID
NCT05477095

About UB-313 + Placebo

UB-313 + Placebo is a phase 1 stage product being developed by Vaxxinity for Migraine. The current trial status is completed. This product is registered under clinical trial identifier NCT05477095. Target conditions include Migraine.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT05477095Phase 1Completed

Competing Products

20 competing products in Migraine

See all competitors
ProductCompanyStageHype Score
ABP-450AEON BiopharmaPhase 2
44
Lasmiditan + PlaceboEli LillyPhase 3
77
Placebo + LY2300559Eli LillyPhase 2
52
lasmiditan 200 mg + Sumatriptan + matching placeboEli LillyPhase 1
33
ABP-450 + PlaceboAEON BiopharmaPhase 2
44
Lasmiditan + PlaceboEli LillyPhase 2
52
Ketorolac + Prochlorperazine + DiphenhydramineAssertio HoldingsPhase 2
44
Galcanezumab + ErenumabEli LillyApproved
85
Aricept (donepezil hydrochloride)EisaiPhase 2
52
E2007EisaiPhase 2
52
Galcanezumab + Rimegepant + Placebo + PlaceboEli LillyApproved
85
Galcanezumab + PlaceboEli LillyPhase 3
77
Lasmiditan + PlaceboEli LillyPhase 2
52
Galcanezumab + PlaceboEli LillyPhase 3
77
LasmiditanEli LillyPhase 3
77
Galcanezumab Prefilled Syringe + PlaceboEli LillyPhase 2
52
Emgality 120 MG in 1 ML Prefilled SyringeEli LillyApproved
85
GalcanezumabEli LillyPre-clinical
23
Galcanezumab + PlaceboEli LillyPhase 3
77
Galcanezumab + PlaceboEli LillyPhase 2
52

Other Products from Vaxxinity

UB-612 + BNT162b2 vaccine + ChAdOx1-S vaccine + Sinopharm BIBPPhase 3
69
UB-612Phase 2/3
57
UB-612 + PlaceboPhase 2
44
UB-312 + PlaceboPhase 1
25
UB-612Phase 1
25